Holding Subsidiary Bumetanide Injection Approved for Supplementary Application

Sina Finance News reported on March 31 that Lianhuan Pharmaceutical announced that its holding subsidiary, Changle Pharmaceutical, recently received the approved and issued notification letter for the supplemental application of Bufematinib Injection from the National Medical Products Administration. The approval includes an increase in the 1ml:0.5mg specification, changes in production process parameters, batch size, and packaging materials. As of the disclosure date of the announcement, the domestic sample hospital sales of this drug in 2024 are approximately 290 million yuan, about 103 million yuan in the first three quarters of 2025, with Changle Pharmaceutical's R&D investment of around 5.416 million yuan. By 2026, the company has obtained three production licenses. This approval is not expected to have a significant impact on the company's performance in the near term, and there is uncertainty in drug sales.